Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "cell therapy" wg kryterium: Temat


Tytuł:
Terapia komórkowa w schorzeniach zwyrodnieniowych siatkówki – nadzieje i zagrożenia
Cell therapy in degenerative retinal diseases: expectations and threats
Autorzy:
Machalińska, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1034206.pdf
Data publikacji:
2020
Wydawca:
Medical Education
Tematy:
komórki macierzyste
terapia komórkowa
zwyrodnienie barwnikowe siatkówki
cell therapy
stem cells
retinitis pigmentosa
Opis:
Currently, for many retinal degenerative diseases there is no effective treatment based on disease etiology. Neurotrophic factors secreted by the applied cells are responsible for improved morphology and function of degenerative retina. Moreover, these cells present immunomodulatory effect and reduce the inflammatory response of the damaged tissue. The best effect is obtained at the initial stage of the disease. Despite promising preliminary results, cell therapy requires further investigation to evaluate its efficacy and long-term safety. It is worth to underline that cell therapy should be conducted only as part of free clinical trials in certified research centers after obtaining the patient's informed consent for treatment
Obecnie brakuje skutecznego leczenia przyczynowego wielu chorób degeneracyjnych siatkówki. Za poprawę morfologii i funkcji degenerującej siatkówki odpowiadają czynniki neurotroficzne wydzielane przez aplikowane komórki, które wykazują dodatkowo wpływ immunomodulujący i redukują odpowiedź zapalną uszkodzonej tkanki. Najlepsze efekty uzyskuje się w początkowym stadium zaawansowania choroby. Pomimo obiecujących wstępnych wyników terapia komórkowa wymaga dalszych badań oceniających jej skuteczność i długoterminowe bezpieczeństwo. Ponadto powinna być prowadzona tylko w ramach bezpłatnych badań klinicznych w certyfikowanych ośrodkach naukowo-badawczych po uzyskaniu świadomej zgody pacjenta na leczenie.
Źródło:
OphthaTherapy; 2020, 7, 1; 30-35
2353-7175
2543-9987
Pojawia się w:
OphthaTherapy
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Potential therapeutic application of mesenchymal stem cells in COVID-19 complications
Autorzy:
Kolanko, Emanuel
Mazurski, Adam
Czekaj, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/2108204.pdf
Data publikacji:
2021-12-22
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
occupational diseases
mesenchymal stem cells
cell therapy
complementary therapy
COVID-19
SARS-CoV-2 mutations
Opis:
Mesenchymal stem cells (MSCs) have remarkable immunomodulatory properties, low immunogenicity, and paracrine properties as well as the ability to differentiate into multiple cell lines. These properties make them potential candidates for clinical applications in the treatment of neurodegenerative, cardiovascular, and lung diseases, which may be occupational diseases. Preclinical studies using experimental animal models have demonstrated regenerative properties of MSCs in diseases such as silicosis and occupational asthma. Currently, treatment of the novel disease COVID-19 could be enhanced by using MSC therapies. This disease affects many professional groups with great intensity and its consequences might be considered as an occupational disease. It is a significant public health problem and a therapeutic challenge. Despite the development of vaccines against COVID-19, there is growing concern about the emergence of new mutations of the SARS-CoV-2 virus in addition to the known alpha, beta, gamma, and delta variants. There is still no effective COVID-19 treatment and the existing ones only play a supporting role. MSCs offer treatment possibilities as an alternative or complementary therapy. The clinical trials to date using MSCs in patients with COVID-19 give hope for the safe and effective use of this stem cell population.
Źródło:
Medycyna Pracy; 2021, 72, 6; 693-700
0465-5893
2353-1339
Pojawia się w:
Medycyna Pracy
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer
Autorzy:
Günzburg, Walter
Salmons, Brian
Powiązania:
https://bibliotekanauki.pl/articles/1041363.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cytochrome P450
chemotherapy
genetically modified cells
cell therapy
encapsulated cells
pancreatic cancer
Opis:
Although approved for the treatment of pancreatic cancer, the chemotherapeutic agent ifosfamide is not an effective therapy for this type of tumour. Ifosfamide must be activated by cytochrome P450 (P450) enzymes in the liver, initially to a short lived intermediate and then to toxic metabolites that are subsequently distributed by the circulatory system. Particularly for pancreatic cancer, this liver-mediated conversion results in relatively high systemic toxicities and poor therapeutic concentrations at the liver-distant site of the tumour. Activation of ifosfamide at the site of the tumour may allow lower doses to be used, while increasing the therapeutic index due to the resultant active concentrations generated locally. A cell-based therapy has been conceived where encapsulated, 293-derived cells genetically modified to overexpress a cytochrome P450 enzyme, are implanted near solid tumours. The cells are encapsulated in polymers of cellulose sulphate in order to provide a means of immunoprotection in vivo as well as to physically constrain them to the vicinity of the tumour. A major advantage of this strategy is that it allows one standard cell line to be applied to all patients and this approach can be extended to the treatment of other tumour types. After proof of principle studies in animal models, a phase I/II clinical trial was initiated in patients with stage III/IV nonresectable pancreatic cancer. Encapsulated cells were angiographically placed into the tumour vasculature of 14 patients and followed by systemic low dose ifosfamide treatment. Angiographic delivery of encapsulated cells proved feasible in all but one patient, and was well tolerated with no capsule or ifosfamide treatment-related adverse events. Four of the treated patients showed tumour regressions after capsule delivery and ifosfamide treatment in computer-tomography scans. The other 10 patients showed no further tumour growth (i.e. stable disease) during 20 weeks observation period. The median life expectancy of the patient collective was extended two fold as compared to age and status matched historical controls, with a 3-fold improvement in one year survival being attained. Evidence for a clinical benefit of the treatment was also obtained on the basis of standard parameters for quality of life. This approach has been evaluated by the European Medicines Evaluation Agency (EMEA) and orphan drug status has been granted. A pivotal clinical trial is now being planned with the help of the EMEA. Taken together, the data from this clinical trial suggest that encapsulated cytochrome P450-expressing cells combined with chemotherapy may be useful for the local treatment of a number of solid tumours and support the performance of further clinical studies of this new treatment.
Źródło:
Acta Biochimica Polonica; 2005, 52, 3; 601-607
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cell therapy for regenerative medicine: facts and controversy
Fakty i kontrowersje związane z terapią komórkową w medycynie regeneracyjnej
Autorzy:
Sarnowska, Anna
Machaliński, Bogusław
Radoszkiewicz, Klaudia
Bużańska, Leonora
Powiązania:
https://bibliotekanauki.pl/articles/2121315.pdf
Data publikacji:
2022
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
cell therapy
regenerative medicine
human mesenchymal stem cells
human induced pluripotent stem cells
Opis:
Cellular therapy, as a part of regenerative medicine, implies to the treatment of human disorders with cells as a medical product, so called – “living drugs”. Usually such therapy is applied when other alternative efficient pharmacological therapies are not available. Stem cells of different origin: 1) tissue specific e.g. hematopethic, epithelial, neuronal, limbal; 2) mesenchymal stem cells (MSC) harvested from variety of tissues; 3) pluripotent stem cells: embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) – serve as a source of cells for regenerative medicine application, depending upon disease and application re- quirements. Currently MSC are the type of stem cells that are most frequently used in registered regenerative medicine clinical trials. In this paper we provide the information on the application of cell therapy in orthopedics, hematology, ophthalmology, dermatology, gastrology and neurology. The influence of origin of MSCs and iPSCs on their mode of action as therapeutic, regenerative agents are discussed. Advantages and disadvantages of application of different cell types for cell therapy are underlined. Last, but not least current low regulations in Poland and requirements of European regulatory bodies for cell therapy are pointed out and discussed.
Źródło:
Nauka; 2021, 4; 67-92
1231-8515
Pojawia się w:
Nauka
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Perspectives of use of bone marrow cells in future therapy of brain diseases
Możliwosci wykorzystania komórek szpiku kostnego w przyszłej terapii chorób mózgu
Autorzy:
Opydo-Chanek, Małgorzata
Pasiut, Szymon
Powiązania:
https://bibliotekanauki.pl/articles/1938534.pdf
Data publikacji:
2007
Wydawca:
Akademia Wychowania Fizycznego im. Bronisława Czecha w Krakowie
Tematy:
Bone Marrow Cells
cell therapy
Brain
Transplantation
Rehabilitation
komórki szpiku kostnego
terapia komórkowa
mózg
transplantacja
rehabilitacja
Opis:
Medical problems associated with the increasing number of patients suffering from brain diseases have resulted in a constant search for effective therapeutics. Considering the complicated pathological processes occurring in diseases of the central nervous system and the limited capability of the neural tissue to regenerate, therapy of neurological diseases is extremely difficult. The lack of efficient medical treatment results in complex problems associated with rehabilitation and thus in functional disturbances, which prevent patients from restoring their independence and returning to complete, also professional, activity, Cell therapy has recently been considered as a possible approach in the treatment of brain diseases. Its aim is to supply pathologically changed brain tissue with factors promoting regeneration and with cells that may replace the damaged ones. Bone marrow cells have become a potential source of cells in this type of therapy. Bone marrow contains at least two major kinds of stem cells: haematopoietic stem cells, which give rise to the blood cells and mesenchymal stem cells, which can differentiate into cells of mesenchymal lineage and produce an array of growth factors essential for repair. The review presents the achievements of studies on use of bone marrow cells in the therapy of various brain diseases of traumatic or neurodegenerative aetiology.
Źródło:
Medical Rehabilitation; 2007, 11(1); 31-39
1427-9622
1896-3250
Pojawia się w:
Medical Rehabilitation
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
On the analysis of a mathematical model of CAR-T cell therapy for glioblastoma: Insights from a mathematical model
Autorzy:
Bodnar, Marek
Foryś, Urszula
Piotrowska, Monika J.
Bodzioch, Mariusz
Romero-Rosales, Jose A.
Belmonte-Beitia, Juan
Powiązania:
https://bibliotekanauki.pl/articles/24200684.pdf
Data publikacji:
2023
Wydawca:
Uniwersytet Zielonogórski. Oficyna Wydawnicza
Tematy:
glioblastoma
CAR-T cell therapy
mathematical modelling
periodic treatment
glejak wielopostaciowy
terapia CAR-T
modelowanie matematyczne
Opis:
Chimeric antigen receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. Its success has led, in recent years, to its use being tested for different solid tumours, including glioblastoma, a type of primary brain tumour, characterised by aggressiveness and recurrence. This paper presents an analytical study of a mathematical model describing the competition of CAR-T and glioblastoma tumour cells, taking into account their immunosuppressive capacity. The model is formulated in a general way, and its basic properties are investigated. However, most of the analysis considers the model with exponential tumour growth, assuming this growth type for simplicity. The existence and stability of steady states are studied, and the subsequent focus is on two different types of treatment: constant and periodic. Finally, protocols for CAR-T cell therapy of glioblastoma are numerically derived; these are aimed at preventing the tumour from reaching a critical size and at prolonging the patients’ survival time as much as possible. The analytical and numerical results provide theoretical support for the treatment of glioblastoma using CAR-T cells.
Źródło:
International Journal of Applied Mathematics and Computer Science; 2023, 33, 3; 379--394
1641-876X
2083-8492
Pojawia się w:
International Journal of Applied Mathematics and Computer Science
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Komórki macierzyste w neurologii
Stem cells in neurology
Autorzy:
Gójska, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1058918.pdf
Data publikacji:
2008
Wydawca:
Medical Communications
Tematy:
cell therapy
nervous system
neurogenesis
progenitor cells
stem cells
komórki macierzyste
komórki progenitorowe
neurogeneza
terapia komórkowa
układ nerwowy
Opis:
Human brain is a very complex biological system considering its cytoarchitecture, neuronal network, localisation of functional regions and integration. Until second half of the XX century it was believed that CNS is deprived of regenerative processes. At present there are many studies that confirm constant formation of new neurones in the human brain. However, this process of cell exchange is far less effective in comparison with the regeneration and functional renewal of other tissues of our organism. In the following article we present current data on local neurogenesis in the adult brain. There are at least 3 regions of CNS where cell proliferembrioation takes place: subventricular zone – SVZ, subgranular zone – SGZ and posterior periventricular area – PPv. It has been estimated that single radial glial cell, which is the progenitor of cells residing in the aforementioned regions of the brain, would be enough to form 4×107 of new brains. Other tissues of our organism could become another source of stem cells for brain regeneration. This solution is tempting when we consider a theory of peripheral blood stem cells that reside in different organ niches. Injured tissue produces higher amounts of chemokines such as SDF-1 or LIF that causes increased migration of stem cells towards the “calling- for-help” organ. The last part of the article presents the progress that has been made in regeneration therapies of certain neurological disorders: cerebral stroke, Parkinson’s disease, multiple sclerosis, spinal cord injuries, amyotrophic lateral sclerosis, Huntigton’s disease and Alzheimer’s disease.
Mózg człowieka jest bardzo skomplikowanym biologicznym systemem pod względem cytoarchitektury, sieci neuronalnej, lokalizacji ośrodków funkcjonalnych oraz integracji. Do drugiej połowy XX wieku panował pogląd, że po okresie rozwoju OUN jest pozbawiony jakiejkolwiek zdolności regeneracyjnej. Istnieje obecnie wiele badań potwierdzających fakt, iż w dorosłym mózgu ludzi ma miejsce ciągły proces tworzenia się nowych neuronów, chociaż oczywiście proces wymiany komórek ośrodkowego układu nerwowego prezentuje się nie najlepiej w porównaniu z regeneracją i funkcjonalną odnową, które mają miejsce w innych organach naszego organizmu. W poniższym artykule przedstawione zostały aktualne dane dotyczące miejscowej neurogenezy w dojrzałym mózgu. W mózgu człowieka znajdują się przynajmniej 3 obszary, gdzie mają miejsce procesy proliferacji komórkowej: strefa przykomorowa (subventricularzone, SVZ), strefa przyziarnista (subgranularzone, SGZ), oraz tylna strefa okołokomorowa (posterior periventricular area, PPv). Wyliczono, że pojedyncza komórka gleju radialnego, której mitotyczni potomkowie rezydują w wymienionych strefach rozrodczych, wystarczyłaby do utworzenia 4x107 mózgów. Innym źródłem odnowy dla mózgu mogłyby stać się komórki macierzyste pozyskiwane z innych tkanek naszego organizmu. Takie rozwiązanie znajduje swoje uzasadnienie w ramach teorii o krążących w krwi obwodowej komórkach macierzystych zasiedlających poszczególne nisze narządowe. Znacznie upraszczając, uszkodzony narząd wydziela zwiększoną ilość chemoatraktantów, takich jak SDF-1 czy LIF, i tym przyciąga do siebie zwiększoną ilość komórek macierzystych. W dalszej części artykułu przedstawiono postęp, jaki dokonał się w terapiach regeneracyjnych w przypadku niektórych schorzeń neurologicznych: udaru mózgu, choroby Parkinsona, stwardnienia rozsianego, urazów rdzenia, stwardnienia zanikowego bocznego, choroby Huntingtona oraz choroby Alzheimera.
Źródło:
Aktualności Neurologiczne; 2008, 8, 1; 39-48
1641-9227
2451-0696
Pojawia się w:
Aktualności Neurologiczne
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cell therapy in surgical treatment of fistulas. Preliminary results
Autorzy:
Piejko, Marcin
Romaniszyn, Michał
Borowczyk-Michałowska, Julia
Drukała, Justyna
Wałęga, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/1393600.pdf
Data publikacji:
2017
Wydawca:
Index Copernicus International
Tematy:
anal fistula
stem cell-based therapy
recurrent fistula
regenerative medicine
rectovaginal fistula
Opis:
Risk of recurrence after surgical treatment of a recurrent fistula is up to 50%. It has be known that more aggressive surgical treatment is associated with a high risk of anal sphincter damage and leads to incontinence. Several studies have been designed to elaborate minimally invasive treatment of rectovaginal and anal fistulas. The properties of Adipose-derived Stem Cells (ASC) significantly enhance a natural healing potency. Here, we present our experience with combined surgical and cell therapy in the treatment of fistulas. Materials and Methods: Four patients were enrolled in our study after unsuccessful treatments in the past – patients 1-3 with rectovaginal fistulas including two women after graciloplasty, and patient 4 - a male with complex perianal fistula. Adipose tissue was obtained from subcutaneous tissue. ASCs were isolated, cultured up to 10+/-2 mln cells and injected into the walls of fistulas. Follow-up physical examination and anoscopy were performed at 1, 4, 8, and 12 weeks, 6 and 12 months after implantation. Results: Up to 8 weeks after ASC implantation, symptoms of fistulas’ tracts disappeared. At 8 weeks, in patients 1-3, communication between vaginal and rectal openings was closed and at 12-16 w. intestinal continuity was restored in patient 3 and 4. After a 6-month follow-up, the fistula tract of patient 4 was closed. Up to 12 m. after ASC implantation no recurrences or adverse events were observed. Conclusion: ASCs combined with surgical pre-treated fistula tracts were used in four patients. All of them were healed. This encouraging result needs further trials to evaluate the clinical efficiency and the cost-effectiveness ratio.
Źródło:
Polish Journal of Surgery; 2017, 89, 3; 48-51
0032-373X
2299-2847
Pojawia się w:
Polish Journal of Surgery
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Macrophages in Diabetes Mellitus: A Review on Understanding of Macrophage Function
Autorzy:
Chatterjee, Susraba
Guria, Srikanta
Powiązania:
https://bibliotekanauki.pl/articles/1059398.pdf
Data publikacji:
2019
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
Alloxan
Beta-cell Therapy
Cytokines
Diabetes mellitus
Diabetic Nephropathy
Diabetic Retinopathy
Macrophage
Macrophage Type 1
Macrophage Type 2
Streptozotocin
Opis:
Diabetes mellitus (DM) causes millions of deaths all over the world. Immune system contains macrophages that play very important role in DM. Excessive secretion of different cytokines can induce the DM development. Diabetes mellitus (DM) also affect the function of macrophage. We review the important findings regarding the role of macrophage in DM. This review may emphasize future direction towards development of novel immune-modulatory therapeutic intervention.
Źródło:
World Scientific News; 2019, 134, 2; 319-325
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Czy terapia komórkami macierzystymi to przyszłość w leczeniu pacjentów z Mózgowym Porażeniem Dziecięcym?
Is stem cell therapy a future for the treatment of patients with Cerebral Palsy?
Autorzy:
Krukowska-Andrzejczyk, Barbara
Cebula, Agnieszka
Głuszkiewicz, Ewa
Kopyta, Ilona
Powiązania:
https://bibliotekanauki.pl/articles/1819304.pdf
Data publikacji:
2019
Wydawca:
Polskie Towarzystwo Neurologów Dziecięcych
Tematy:
mózgowe porażenie dziecięce
choroby układu nerwowego
dziecko
komórki macierzyste
terapia komórkowa
cerebral palsy
nervous system disease
child
stem cell
cell based therapy
Opis:
Mózgowe porażenie dziecięce (MPD) jest jedną z najczęstszych przyczyn niepełnosprawności wśród dzieci, a terapia MPD jest jednym z głównych wyzwań neurologii dziecięcej. Pomimo dowodów na skuteczność rehabilitacji i interwencji chirurgicznych na poprawę funkcjonowania pacjentów z MPD, brak jest obecnie skutecznego leczenia, które zmniejszałoby nasilenie choroby i wpływało na trwałą poprawę funkcjonowania pacjentów. Jednym z priorytetowych tematów badawczych jest obecnie zastosowanie komórek macierzystych w terapii chorób neurologicznych, w tym w MPD. W ostatnich kilku latach wzrasta liczba dokonanych podań komórek macierzystych u pacjentów z MPD, jak również prowadzonych badań klinicznych. Niniejszy artykuł przedstawia aktualny stan wiedzy dotyczący terapii MPD komórkami macierzystymi w celu odpowiedzi na pytanie czy terapia komórkami macierzystymi to szansa na bardziej efektywne leczenie pacjentów z MPD.
Cerebral palsy (CP) is one of the most common causes of disability among children and CP therapy is one of the main challenges in pediatric neurology. Despite evidence of the effectiveness of rehabilitation and surgical interventions to improve the functioning of patients with CP, there is no effective treatment that would reduce the severity of the disease and affect the permanent improvement of functioning. One of the leading topics of current research is the use of stem cells in the treatment of neurological diseases, including CP. In the last few years the number of stem cell applications in CP as well as clinical trials has been increasing. This article presents the current state of knowledge regarding stem cell therapy in order to answer the question whether stem cell therapy is an opportunity for more effective treatment of patients with CP.
Źródło:
Neurologia Dziecięca; 2019, 28, 56; 27-38
1230-3690
2451-1897
Pojawia się w:
Neurologia Dziecięca
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Retrospective assessment of everolimus treatment in patients suffering from advanced renal cell carcinoma
Autorzy:
Hernik, Paweł
Kruczała, Maksymilian
Ziobro, Marek
Powiązania:
https://bibliotekanauki.pl/articles/773514.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
everolimus
renal cell carcinoma
targeted therapy
Opis:
Objective: Results of second-line everolimus treatment in clear cell renal carcinoma. Material and methods: Clinical data of 32 patients of the Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute (Krakow Branch) treated with second-line everolimus between 2011 and 2016 were analysed. Results: Median progression-free survival was 7 months. Stable disease was observed in 24 cases. Adverse events occurred in 59% of all patients, and the majority were mild and moderate (G1 and G2) according to CTCAE. The most frequent adverse events included anaemia, stomatitis, rash and fatigue. Conclusion: Molecularly targeted drugs offer the only effective and available therapy in Poland, which can be administered in patients with advanced renal cell carcinoma. Second-line everolimus is a valuable therapeutic option in the above mentioned group (following progression on first-line TKI therapy), especially when it is necessary to avoid the accumulation of similar adverse events after TKI treatment (different toxicity profiles).
Źródło:
OncoReview; 2017, 7, 2; 88-91
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
New integrative PDT method of cancer treatment by means of laser, magnetic therapy and herbal ferromagnetics
Autorzy:
Arakelyan, Hayk S.
Powiązania:
https://bibliotekanauki.pl/articles/773493.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
cancer
integrative photodynamic therapy
tumor’s cell
Opis:
Integrative photodynamic therapy (IPDT) of tumors consists of combined use of different curable factors that extremely increase the effectiveness of IPDT. The leading curable effect of PDT is determined by developing of aggressive photochemical reactions in the tumor. The main destructive factor of these reactions is the generation of free radicals that kill tumor’s cells. For PDT efficacy increasing it is necessary to solve the following problems and assure: easiness of production or synthesis; accumulation high selectivity regarding tumor tissue; low toxicity in light and darkness; singled oxygen generation high quant output; promptly elimination from the organism after the treatment procedure; good absorption in spectral intervals most transparent for tissues (red and infrared intervals); optimal interconversion between quant output and fluorescence quant output. PDT effectiveness may be significantly increased by means of: increasing of photosentisizer selectivity and accumulation in tumor tissue; increasing of tumor tissue photochemical destruction caused by photosensitizer. Realization of integrative PDT using Cyber Laser may increase tumor therapy effectiveness to 94–96% and at the same time will establish a new direction in PDT.
Źródło:
OncoReview; 2014, 4, 4; A171-A174
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Merkel cell carcinoma
Autorzy:
Markiewicz, Jarosław
Dziewirski, Wirginiusz
Powiązania:
https://bibliotekanauki.pl/articles/1065725.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
Merkel cell carcinoma
cutaneous neuroendocrine carcinoma
therapy
Opis:
Merkel cell carcinoma (MCC) is a rare cutaneous malignancy, with aggressive behaviour. The discovery of MCC polyomavirus (MCPyV) provided a major insight into pathogenesis of MCC, as MCPyV is present in most MCC tumours. The primary treatment of locoregional MCC is surgery, and sentinel lymph node biopsy should be performed in all cases at clinical stage I-II. Adjuvant radiotherapy decreases disease recurrences in stage I-III of the disease. Chemotherapy is primarily used for palliation and provides overall response rates of approximately 70%; however, the disease often recurs within a few months. All cases of MCC should be managed in an experienced multidisciplinary setting.
Źródło:
OncoReview; 2014, 4, 3; A121-125
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Analysis of global dynamics for HIV-infection of CD4+T cells and its treatment
Autorzy:
Bodzioch, Mariusz
Choiński, Marcin
Foryś, Urszula
Powiązania:
https://bibliotekanauki.pl/articles/747663.pdf
Data publikacji:
2018
Wydawca:
Polskie Towarzystwo Matematyczne
Tematy:
HIV, CD4+T cell, IL-2, HAART therapy, global stability
HIV, limfocyty CD4$^+$T, interleukina IL-2, terapia HAART, globalna stabilność
Opis:
Przeciwwirusowe terapie dla pacjentów z wirusem HIV są stale ulepszane. Podawanie kombinacji dwóch lub więcej leków powoduje spadek liczby wirusów poniżej poziomu detekcji u wielu pacjentów. W szczególności połączenie wysoce efektywnej terapii antyretrowirusowej (HAART) z aktywatorem immunologicznym (interleukiną 2, IL-2) wydaje się stanowić skuteczną metodę długookresowej kontroli replikacji wirusa  HIV in vivo.W naszym artykule zaproponowaliśmy matematyczny model odpowiedzi odpornościowej dla pacjentów z wirusem HIV przy zastosowaniu połączonej terapii  HAART i IL-2. Zbadaliśmy dynamikę modelu w poszukiwaniu warunków, przy których układ odpornościowy odnawia się dzięki takiej terapii. Z~analitycznego punltu widzenia oznacza to globalną stabilność stanu stacjonarnego odpowiadającego zdrowemu organizmowi. Analiza matematyczna została uzupełniona symulacjami komputerowymi.
Antiviral therapy for HIV-infected patients has greatly improved in recent years. Administration of drug combinations consisting of two or more different drugs can reduce and maintain virus load below detection level in many patients. Cyclic administration of the immune activator interleukin-2 (IL-2) in combination with highly active antiretroviral therapy (HAART) has been suggested as an effective strategy to realize long-term control of HIV replication in vivo. In this article, we formulate a mathematical model of immune response for HIV-infected individual in the presence of HAART and IL-2. We look  for the conditions under which the immune system recovers by applying IL-2 as an immune activator along with HAART. From analytical point of view this means global stability of the disease-free equilibrium. Comprehensive numerical simulations are presented to illustrate the analytical results.
Źródło:
Mathematica Applicanda; 2018, 46, 1
1730-2668
2299-4009
Pojawia się w:
Mathematica Applicanda
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Elevated expression of serine/threonine phosphatase type 5 correlates with malignant proliferation in human osteosarcoma
Autorzy:
Han, Kun
Gan, Zhihua
Lin, Shuchen
Hu, Haiyan
Shen, Zan
Min, Daliu
Powiązania:
https://bibliotekanauki.pl/articles/1038676.pdf
Data publikacji:
2017
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cell proliferation
lentivirus
Osteosarcoma
PP5
siRNA
targeted therapy
Opis:
Osteosarcoma is the most common primary malignant bone tumor in adolescents and young adults. However, the involvement of serine/threonine phosphatase type 5 (PP5) in osteosarcoma remains unclear. The aim of this study was to evaluate the functional role of PP5 in osteosarcoma cells. Firstly, we found that PP5 is widely expressed in several human osteosarcoma cell lines. Then we used lentivirus-delivered siRNA to silence PP5 expression in Saos-2 and U2OS cell lines. Knockdown of endogenous PP5 expression by shRNA-expressing lentivirus significantly decreased the viability and proliferation of the osteosarcoma cells. Moreover, FACS analysis showed that knockdown of PP5 expression induced a significant arrest in the G0/G1 phase of the cell cycle, which was associated with the inhibition of cell proliferation. Therefore, knockdown of PP5 is likely to provide a novel alternative to targeted therapy of osteosarcoma and deserves further investigation.
Źródło:
Acta Biochimica Polonica; 2017, 64, 1; 11-16
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies